Table 1. Validation of each method used in the virtual screening workflow.
Set of Compounds | Number of Compounds | Structure-based pharmacophore screening | Electrostatic/shape similarity analysis | Global virtual screening | ||
anti pharmacophore | partial agonist pharmacophore | |||||
in vacuo conformations | in vacuo conformations | docking poses | ||||
Partial Agonists | 19 | 12 | 10 | 8 | 5 | 5 |
Full Agonists | 135 | 31 | 11 | 7 | 1 | 1 |
Decoys | 3122 | 2204 | 964 | 382 | 16 | 16 |
Enrichment Factor (EF) | 2.45 | 1.90 | 1.98 | 11.28 | 39.19 | |
EFmax | 24.27 | 187.25 | 98.50 | 49.63 | 172.42 | |
Sensitivity (Se) | 77.04% | 83.33% | 80.00% | 62.50% | 26.32% | |
Specificity (Sp) | 29.45% | 56.38% | 60.10% | 95.63% | 99.49% |
A dataset of 19 known PPARγ partial agonists, 135 known PPARγ full agonists and 3122 decoys extracted from the DUD database were used. The values represent the number of compounds from each set that survived each step when applied sequentially.